CRDF vs. PLRX, BCAX, PRTA, DNTH, CRMD, ETNB, QURE, CGEM, PHAR, and LENZ
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), Prothena (PRTA), Dianthus Therapeutics (DNTH), CorMedix (CRMD), 89bio (ETNB), uniQure (QURE), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs.
Pliant Therapeutics (NASDAQ:PLRX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Pliant Therapeutics received 34 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 64.06% of users gave Cardiff Oncology an outperform vote.
Cardiff Oncology has lower revenue, but higher earnings than Pliant Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pliant Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Pliant Therapeutics' return on equity of -48.91% beat Cardiff Oncology's return on equity.
97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by company insiders. Comparatively, 7.6% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Pliant Therapeutics had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Pliant Therapeutics and 0 mentions for Cardiff Oncology. Pliant Therapeutics' average media sentiment score of 0.22 beat Cardiff Oncology's score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the media.
Pliant Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Pliant Therapeutics presently has a consensus target price of $40.50, indicating a potential upside of 261.80%. Cardiff Oncology has a consensus target price of $10.33, indicating a potential upside of 193.14%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Cardiff Oncology.
Summary
Pliant Therapeutics beats Cardiff Oncology on 15 of the 19 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 1/21/2025 by MarketBeat.com Staff
